Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 6/20 | 0.45 |
| ▸ | HSD17B2 | P37059 | 6/20 | 0.45 |
| ▸ | HSD17B14 | Q9BPX1 | 9/20 | 0.44 |
| ▸ | ERN1 | O75460 | 3/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17788165 | 0.77 | HSD17B1 (0.52) | HSD17B1HSD17B2HSD17B14 | |
| SCHEMBL15849717 | 0.77 | HSD17B14 (0.57) | HSD17B1HSD17B2HSD17B14CNR2 | |
| SCHEMBL12468458 | 0.77 | ALDH1A1 (0.56) | HSD17B1HSD17B2HSD17B14 | |
| SCHEMBL15849592 | 0.74 | CTSA (0.45) | HSD17B1HSD17B2HSD17B14CNR1 | |
| SCHEMBL16385241 | 0.74 | HSD17B1 (0.49) | HSD17B1HSD17B2 | |
| SCHEMBL15849615 | 0.73 | MEN1 (0.50) | HSD17B14CNR2CNR1 | |
| SCHEMBL16731618 | 0.72 | SCN9A (0.53) | SCN9A | |
| SCHEMBL12467631 | 0.71 | CNR2 (0.54) | HSD17B2CNR2 | |
| SCHEMBL14152091 | 0.71 | KMO (0.64) | HSD17B1HSD17B2HSD17B14ERN1CNR2 | |
| SCHEMBL9966066 | 0.69 | RAB9A (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110182854-A1 | HCV PROTEASE INHIBITORS | SEQUOIA PHARMACEUTICALS, INC. (US) | 2011-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110182854-A1 | HCV PROTEASE INHIBITORS | SERPINB1, CTSC, HPN | HSD17B1 806/4885HSD17B2 1504/4885HSD17B14 533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.